Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu Province, China.
Department of Neurology, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215006, Jiangsu Province, China.
Neurol Sci. 2024 Feb;45(2):495-506. doi: 10.1007/s10072-023-07096-x. Epub 2023 Oct 4.
It remains unclear whether bridging therapy can achieve better neurologic outcomes than direct endovascular thrombectomy (EVT) in patients with posterior ischemic stroke.
We systematically searched PubMed, EMBASE, and Cochrane databases with posterior artery occlusion treated with bridging therapy vs. EVT. Efficacy was assessed based on functional independence at 90 days and successful recanalization, whereas safety was assessed by mortality, rate of symptomatic intracranial hemorrhage (sICH), and occurrence of any hemorrhage. All data were analyzed with Review Manager software v5.3 and the risk of bias was determined using the Methodological Index for Non-randomized Studies.
We included 17 studies with a total of 3278 patients (1211 in the bridging therapy group and 2067 in the EVT group). Patients in the bridging group had a better functional outcome at 90 days, as evidenced by a higher proportion with a Modified Rankin Scale (mRS) score of 0-2 compared with the EVT group (odds ratio (OR) = 1.83, 95% confidence interval (CI): 1.54-2.19, P < 0.01), while no difference in mRS score of 0-3 (OR = 1.18, 95% CI: 0.96-1.45, P = 0.11). Patients in the bridging therapy group also had lower 90-day mortality rate (OR = 0.75, 95% CI: 0.59-0.95, P = 0.02). There were no significant differences between groups in rates of successful recanalization (OR = 0.96, 95% CI: 0.74-1.25, P = 0.77), sICH (OR = 1.27, 95% CI: 0.86-1.89, P = 0.24), and hemorrhage (OR = 1.22, 95% CI: 0.60-2.50, P = 0.58).
Among patients with posterior ischemic stroke, bridging therapy may be superior to EVT in achieving a good functional outcome and lowering the mortality without increasing the risks of hemorrhage.
在伴有后循环缺血性卒中的患者中,桥接治疗与直接血管内血栓切除术(EVT)相比是否能实现更好的神经功能结局仍不清楚。
我们系统地检索了 PubMed、EMBASE 和 Cochrane 数据库,纳入了接受桥接治疗与 EVT 治疗的后循环动脉闭塞患者的研究。根据 90 天的功能独立性和成功再通来评估疗效,通过死亡率、症状性颅内出血(sICH)发生率和任何出血发生率来评估安全性。所有数据均使用 Review Manager 软件 v5.3 进行分析,并使用非随机研究方法学指数评估偏倚风险。
我们纳入了 17 项研究,共 3278 例患者(桥接治疗组 1211 例,EVT 组 2067 例)。与 EVT 组相比,桥接组患者 90 天的功能结局更好,表现为改良 Rankin 量表(mRS)评分 0-2 的比例更高(比值比 [OR] = 1.83,95%置信区间 [CI]:1.54-2.19,P < 0.01),而 mRS 评分 0-3 的比例无差异(OR = 1.18,95% CI:0.96-1.45,P = 0.11)。桥接治疗组患者的 90 天死亡率也较低(OR = 0.75,95% CI:0.59-0.95,P = 0.02)。两组间再通率(OR = 0.96,95% CI:0.74-1.25,P = 0.77)、sICH 发生率(OR = 1.27,95% CI:0.86-1.89,P = 0.24)和出血发生率(OR = 1.22,95% CI:0.60-2.50,P = 0.58)均无显著差异。
在后循环缺血性卒中患者中,与 EVT 相比,桥接治疗可能在实现良好的功能结局和降低死亡率方面更具优势,而不会增加出血风险。